miRNAs in Cardiac Myxoma: New Pathologic Findings for Potential Therapeutic Opportunities.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Mar 2022
Historique:
received: 18 02 2022
revised: 13 03 2022
accepted: 15 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 9 4 2022
Statut: epublish

Résumé

MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level, contributing to all major cellular processes. The importance of miRNAs in cardiac development, heart function, and valvular heart disease has been shown in recent years, and aberrant expression of miRNA has been reported in various malignancies, such as gastric cancer and breast cancer. Different from other fields of investigation, the role of miRNAs in cardiac tumors still remains difficult to interpret due to the scarcity publications and a lack of narrative focus on this topic. In this article, we summarize the available evidence on miRNAs and cardiac myxomas and propose new pathways for future research. miRNAs play a part in modifying the expression of cardiac transcription factors (miR-335-5p), increasing cell cycle trigger factors (miR-126-3p), interfering with ceramide synthesis (miR-320a), inducing apoptosis (miR-634 and miR-122), suppressing production of interleukins (miR-217), and reducing cell proliferation (miR-218). As such, they have complex and interconnected roles. At present, the study of the complete mechanistic control of miRNA remains a crucial issue, as proper understanding of signaling pathways is essential for the forecasting of therapeutic implications. Other types of cardiac tumors still lack adequate investigation with regard to miRNA. Further research should aim at investigating the causal relationship between different miRNAs and cell overgrowth, considering both myxoma and other histological types of cardiac tumors. We hope that this review will help in understanding this fascinating molecular approach.

Identifiants

pubmed: 35328730
pii: ijms23063309
doi: 10.3390/ijms23063309
pmc: PMC8954653
pii:
doi:

Substances chimiques

MIRN217 microRNA, human 0
MIRN218 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Biochem Biophys Res Commun. 2016 Jun 3;474(3):560-565
pubmed: 27109478
Circ Res. 2015 Feb 13;116(4):751-62
pubmed: 25677521
J Cardiovasc Pharmacol Ther. 2021 Jan;26(1):3-11
pubmed: 32851865
Oncol Lett. 2018 Oct;16(4):4235-4242
pubmed: 30250535
Vascul Pharmacol. 2019 Mar;114:31-48
pubmed: 30389614
Eur Heart J. 2020 Dec 1;41(45):4332-4345
pubmed: 32330934
J Cardiovasc Transl Res. 2020 Jun;13(3):431-450
pubmed: 32642841
J Cell Biochem. 2019 Aug;120(8):13441-13452
pubmed: 30912168
Heart Fail Rev. 2021 Jul;26(4):997-1021
pubmed: 33443726
Front Physiol. 2021 Mar 24;12:650566
pubmed: 33841185
Int J Mol Sci. 2021 May 08;22(9):
pubmed: 34066757
Stem Cells. 2014 Aug;32(8):2229-44
pubmed: 24648336
Int J Mol Sci. 2020 Jun 19;21(12):
pubmed: 32575472
J Tissue Eng Regen Med. 2017 Mar;11(3):787-799
pubmed: 25492026
Heart Vessels. 2018 Nov;33(11):1403-1410
pubmed: 29789901
Cardiovasc Pathol. 2021 Jan - Feb;50:107296
pubmed: 33022373
Curr Cardiol Rev. 2021;17(4):e010621188335
pubmed: 33238844
Int J Mol Sci. 2021 Nov 09;22(22):
pubmed: 34830016
Curr Pharm Des. 2021;27(37):3858-3870
pubmed: 33308116
Cell Death Differ. 2011 Jun;18(6):985-95
pubmed: 21164520
Int J Mol Sci. 2020 Aug 31;21(17):
pubmed: 32878347
Cells. 2021 Nov 09;10(11):
pubmed: 34831320
Int J Mol Sci. 2020 Jan 05;21(1):
pubmed: 31948131
J Mol Cell Cardiol. 2016 May;94:107-121
pubmed: 27056419
Genomics. 2021 Mar;113(2):540-551
pubmed: 33482325
Front Physiol. 2021 Jan 22;11:612722
pubmed: 33551838
J Clin Med. 2021 Sep 27;10(19):
pubmed: 34640448
Cell Regen. 2021 Jun 1;10(1):14
pubmed: 34060005
Oncol Rep. 2015 May;33(5):2606-12
pubmed: 25812649
Biochem Biophys Res Commun. 2017 Aug 26;490(3):713-718
pubmed: 28642131

Auteurs

Antonio Nenna (A)

Cardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

Francesco Loreni (F)

Cardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

Omar Giacinto (O)

Cardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

Camilla Chello (C)

Integrated Biomedical Science and Bioethics, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

Pierluigi Nappi (P)

Cardiology, Università degli Studi di Messina, 98122 Messina, Italy.

Massimo Chello (M)

Cardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.

Francesco Nappi (F)

Cardiac Surgery, Centre Cardiologique du Nord de Saint Denis, 93200 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH